Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.

[1]  Zhenqiu Lin,et al.  Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States , 2021, Circulation. Cardiovascular quality and outcomes.

[2]  Amy Alonzo,et al.  Proportion of days covered as a measure of medication adherence. , 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[4]  G. Filippatos,et al.  Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction , 2021, Circulation.

[5]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[6]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. , 2021, The lancet. Diabetes & endocrinology.

[7]  F. V. Mody,et al.  National Trends in the Use of Sacubitril/Valsartan. , 2021, Journal of cardiac failure.

[8]  V. Montori,et al.  Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities , 2021, Diabetes Care.

[9]  R. Kushner,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply. , 2021, The New England journal of medicine.

[10]  H. Heerspink,et al.  SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications , 2021, The Lancet.

[11]  H. Krumholz,et al.  Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus , 2021, Journal of the American Heart Association.

[12]  F. Greenway,et al.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. , 2021, JAMA.

[13]  V. Montori,et al.  Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. , 2021, JAMA network open.

[14]  Introduction: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[15]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[16]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[17]  W. Gellad,et al.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program , 2020, JAMA network open.

[18]  D. Kazi,et al.  Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. , 2020, JAMA internal medicine.

[19]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[20]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[21]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[23]  C. Mathieu,et al.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.

[24]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[25]  W. Glasheen,et al.  Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. , 2019, American health & drug benefits.

[26]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[27]  W. Glasheen,et al.  Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation. , 2017, Journal of diabetes and its complications.

[28]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[29]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[30]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[31]  Nilay D Shah,et al.  Optum Labs: building a novel node in the learning health care system. , 2014, Health affairs.